The utilization of a mixture containing platelet-rich fibrin and Synthetic Hydroxyapatite (Nanobone) substance in the process of enhancing the volume of the maxillary sinus for medical purposes.
Not Applicable
Completed
- Conditions
- Reduced bone height in the posterior maxilla (1-4 mm)Oral Health
- Registration Number
- ISRCTN99349253
- Lead Sponsor
- SUAVEMED
- Brief Summary
2024 Results article in https://doi.org/10.3390/biomedicines12081661 (added 25/07/2024)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
1. At least eighteen years old
2. Have healed edentulous sites on the posterior maxillae region with 5mm or less residual bone height to place implants in need of sinus graft procedure.
Exclusion Criteria
1. Alcoholism
2. Smoking
3. Drug abuse
4. Diabetes
5. Heart disease
6. Bleeding disorders
7. Weakened immune systems
8. Radiation exposure
9. Bleeding disorders
10. Past or ongoing use of steroids or bisphosphonates
11. Prior bone augmentation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain perception measured using the Visual Analogue Scale during the first week after surgery
- Secondary Outcome Measures
Name Time Method 1. Quality of life measured using the Oral Health Impact Profile 14 translated in Portuguese<br>during the first week after surgery<br>2. Implant osseointegration success rate measured using clinical examination at 6 months after<br>surgery<br>3. Patient registration of analgesic medication usage during the first week after surgery